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A 5 year old child with waxing and waning vesicobullous lesions on exposed parts since two years. Blood
porphyrin levels were increased and Woods lamp revealed erythrodontia. DNA analysis showed the child
was homozygous and both parents were heterozygous for a novel pathogenic mutation V256M in uro-
porphyrinogen decarboxylase gene, thus diagnosed as type II recessive form of porphyria cutanea tarda.
The child responded to sunscreens and antioxidants.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction exposed body parts (face, V of chest, both hands and feet) since lastPorphyrias are a group of disorder characterized by defect in
heme production, resulting in accumulation of toxic heme pre-
cursors. Skin manifestations are common like photosensitivity,
painful burning, vasiculo-bullous lesions, healing with scar for-
mation [1]. Porphyria cutanea tarda (PCT) in children is a rare
biochemical derangement resulting into various dermatological
manifestations. The spectrum of the disease depends upon the
quantitative deﬁcient activity of the heme synthetic enzyme Uro-
porphyrinogen Decarboxylase (UROD). The UROD gene has been
mapped on chromosome 1p34 [2]. More than seventy mutations
have been reported so far on this gene. Approximately 80% of the
PCT are sporadic (type I). Familial form of PCT (type II) is rare. Most
of the cases of PCT type II are autosomal dominant but very rarely
autosomal recessive forms are reported. Sporadic PCT presents in
fourth decade while familial forms manifest at any age. Biallelic
mutations cause severe symptoms that appear early [1].
2. Case
We report a case of a ﬁve years old male child, born to a non-
consanguinous marriage, with complaints of blisters on the sunuscript in signiﬁcant way and
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lesions were present at the same time and there were scars from
healing of previous lesions along-with hypopigmented and hy-
perpigmented macules. He had delayed healing of wounds even
after minor scratches (Fig. 1).
Hypertrichosis was observed over temporal and malar area of
the face, plethora of the central face, neck and upper chest was
noted (Fig. 2). The child also had erosion and brownish discolor-
ation of multiple teeth; Rest of the general physical and systemic
examination was unremarkable. There was no history of other
chronic illness and no history of similar complaints in any of the
family members. Clinically the child was suspected to be having
cutaneous porphyria.
Complete blood count and peripheral smear were unremarkable
except for mild normocytic anaemia, ﬂuorescence test for uropor-
phobilinogen in urine was positive; biopsy taken from the lesion
showed positivity towards periodic acid Schiff's (PAS) staining, test
for porphyrin in blood showed increase in total porphyrin. Liver
function tests revealed Aspartate aminotransferase (AST) 31 U/L,
Alanine aminotransferase (ALT) 41 U/L, Alkaline phosphate (ALP)
223 U/L, Total serum bilirubin 0.4mg/dl (direct 0.1 and indirect 0.3),
total protein 8 mg/dl with a normal albumin:globulin ratio. On
woods lamp examination he was found to have erythrodontia.
Serology for hepatitis B and C were negative.
Blood sample from the child and both parents and were sent for
DNA and mutation analysis which revealed that the child was ho-
mozygous and both parents were heterozygous for a novel muta-
tion V256M in the UROD gene. This mutation has not beenrics. Production and hosting by Elsevier B.V. This is an open access article under the
Fig. 1. Showing multiple vesicobullous lesions on the hands with scar formation.
Fig. 2. Showing hypertrichosis, plethora over temporal and malar area on face.
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causing using Mutation taster and Polyphen databases. UROD
enzyme activity estimation could not be done in our setup due to
ﬁnancial and logistic constraints. He was diagnosed as having type
II (familial) recessive form of PCT.
The child was prescribed regular use of sun screen lotion, beta
carotenoids and vit E with avoidance of exposure to direct sunlight.
After 3 months, the cutaneous lesions of the child had markedly
improved and therewere no fresh lesions. The child continues to be
in follow-up at 12months and there are no fresh lesions, no anemia
and the liver function is normal. We took written informed consent
from the parents for publication of images and reports concerned to
the child.
3. Discussion
Homozygous conditions of PCTare very rare and present early in
childhood with much symptomatology. Quantitative deﬁciency of
UROD enzyme leads to overproduction of 4e8 carboxyl group
substituents in heme synthetic pathway [1]. These products get
deposited in skin, liver and accumulate in plasma. Photo-oxidizedporphyrins are responsible for most of the symptoms [1,2]. Clini-
cally, PCT in child presents as blisters, hypo or hyperpigmented
scars on sun exposed body parts, increase in facial hairs and
fragility of skin, tooth discoloration and mild anaemia [1e3]. In the
present case the child had most of these features.
Family members may be symptomatic or asymptomatic
depending upon the level of deﬁciency of the UROD enzyme. It has
been shown that PCT is associated with hemochromatosis and
hepatitis C. Increased incidence of liver neoplasm has been
observed in patients of PCT [4]. PCT is a multifactorial disease;
alcohol, exogenous hormone, iron overload and human immuno-
deﬁciency virus (HIV) are associated [1]. Our patient had none of
these ﬁndings. Clinically suspected PCT can be conﬁrmed by UROD
activity, porphyrin levels, uroﬂuorescence test, skin biopsy and
mutation analysis [1,5]. Child was homozygous for the mutation
V256M and both parents were heterozygous for the same mutation
explaining autosomal recessive inheritance. In the present case,
none of the family members were symptomatic, except the index
case.
This child is the only issue of his parents and as the family was
not complete so antenatal diagnosis was suggested to the parents.
Few treatment modalities for PCT have been described including
antioxidants, phlebotomy and low dose chloroquine/hydroxy-
chloroquine [6e8]. In the present case, the child was prescribed
antioxidants, avoidance of sun exposure and sun screen lotions
which resulted in signiﬁcant improvement in the skin lesions. Such
patients need to be in long term follow-up to watch for any asso-
ciated conditions and complications.
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